Document Detail


Pentoxifylline in treatment of sarcoidosis.
MedLine Citation:
PMID:  9154873     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The optimal therapy for sarcoidosis remains unclear. Most patients show a short-term response to corticosteroid therapy, but they have to face the risk of significant side effects. Because tumor necrosis factor alpha (TNF) plays a critical role in granuloma formation and sustenance as well as in the progression of sarcoidosis, we investigated pentoxifylline (POF), which exerts TNF-inhibitory activity, as a therapeutic agent in active pulmonary sarcoidosis. Twenty-three previously untreated patients with documented disease progression during the preceding 3 mo were treated with POF (25 mg/kg daily) and followed for 6 mo of therapy. Two patients were lost to follow-up, and three patients discontinued POF therapy because of gastrointestinal side effects; 18 patients were thus evaluated. Eleven patients improved, seven remained stable and, most importantly, none deteriorated. Lung function tests-DL(CO), Pa(O2) and Pa(O2)[exercise]-were significantly improved in the patient group as a whole and increased in a highly significant manner in those who improved. Three patients with corticosteroid-resistant disease progression were additionally treated with a combination of corticosteroids with POF. In all three patients the combination therapy resulted in an immediate complete decrease of disease activity, even after tapering prednisone to 7.5 mg daily or tapering off corticosteroids. These promising results suggest that POF may improve therapeutic regimens in pulmonary sarcoidosis either by sparing or replacing corticosteroids.
Authors:
P Zabel; P Entzian; K Dalhoff; M Schlaak
Related Documents :
1802543 - Specimen cross-contamination by a strain of mycobacterium tuberculosis lacking nitrate ...
3748673 - Perspectives in adolescent tuberculosis: three decades of experience.
6531423 - Dangerousness and violence in hospitalized mentally ill offenders.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of respiratory and critical care medicine     Volume:  155     ISSN:  1073-449X     ISO Abbreviation:  Am. J. Respir. Crit. Care Med.     Publication Date:  1997 May 
Date Detail:
Created Date:  1997-06-03     Completed Date:  1997-06-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9421642     Medline TA:  Am J Respir Crit Care Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1665-9     Citation Subset:  AIM; IM    
Affiliation:
Medizinische Klinik Forschungszentrum Borstel, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Drug Therapy, Combination
Female
Glucocorticoids / administration & dosage
Humans
Male
Pentoxifylline / administration & dosage,  therapeutic use*
Phosphodiesterase Inhibitors / therapeutic use*
Prednisone / administration & dosage
Pulmonary Gas Exchange
Respiratory Mechanics
Sarcoidosis, Pulmonary / drug therapy*,  physiopathology
Tumor Necrosis Factor-alpha / metabolism
Chemical
Reg. No./Substance:
0/Glucocorticoids; 0/Phosphodiesterase Inhibitors; 0/Tumor Necrosis Factor-alpha; 53-03-2/Prednisone; 6493-05-6/Pentoxifylline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated w...
Next Document:  Methacholine responsiveness using the raised volume forced expiration technique in infants.